Angel Biotechnology Hldgs (LON:ABH) and Progenteq announced they will be working together to develop a therapy for the treatment of acute knee injuries. Angel Biotechnology is a contract biomanufacturing company listed on AIM November 2005. The Company specializes in the manufacture and supply of materials for use in early stage drug development and pre-clinical studies. Progenteq was founded by the research group of Professor Charlie Archer at Cardiff University's School of Biosciences and established by Fusion IP to develop novel cartilage replacement.
Under the new contract, Angel will provide the consultancy and development services for Progentaq’s cartillage replacement therapy. Commenting on the contract, Gordon Sherriff, Angel's Chief Operating Officer said: "We are delighted to be working with Progenteq on its novel cell therapy. Being awarded this contract further acknowledges our experience and expertise in the field of regenerative medicine development and manufacturing. Angel's detailed understanding of the regulatory framework for GMP compliance with such therapies has played a key role in being awarded this contact. We are always pleased to be able to offer consultancy services in addition to our manufacturing offering ".
Dominic Griffiths, Director of Progenteq added: "We are tremendously excited by the prospect of this novel cell therapy. Angel is well placed to assist the company in its product development activities and we look forward to working with them as we progress Progenteq towards the clinic."
